何玉凯

何玉凯(Yukai He


教育经历,毕业院校及专业、学位  

9/1980-7/1985             医学学士(Bachelor of Medicine), 广州第一军医大学(现改名为南方医科大学)

9/1985-7/1988             医学硕士(Master of Science in Molecular Biology, 广州第一军医大学(现改名为南方医科大学)生化教研室(导师:徐钤教授)

9/1991-5/1995             医学博士(同等哲学博士,Ph. D. in Molecular Virology)海德堡大学和中国科学院上海生化所联合培养博士。导师:祁国荣, Harold zur Hausen,德国肿瘤研究中心(DKFZ)主任, 2008 Nobel Laureate

博士后(Post-Doctoral Training

12/1994-9/1997           美国匹斯堡大学药理系(Department of Pharmacology, University of Pittsburgh, School of Medicine)导师:Leaf Huang

工作任职经历:

7/1988-7/1990             助教:广州第一军医大学(现改名为南方医科大学)生化教研室

7/1990-9/1991             讲师:广州第一军医大学(现改名为南方医科大学)生化教研室

12/1994-9/1997           研究助理(Research Associate):美国匹斯堡大学药理系

9/1997-12/1999           讲师(Instructor):美国匹斯堡大学药理系

                 

1/2000-6/2003             研究助理教授(Research Assistant Professor):美国匹斯堡大学皮肤系

7/2003-7/2007             助理教授 (Tenure track Assistant professor): 美国匹斯堡大学皮肤系

8/2007- 6/2012            副教授 (tenure track), 乔治亚州研究联合杰出疫苗研究者(GRA Distinguished Vaccine Investigator),乔治亚州肿瘤研究中心,奥古斯塔大学

7/2012-6/2015             终身副教授 (Tenured Associate Professor), 乔治亚州研究联合杰出疫苗研究者(GRA Distinguished Vaccine Investigator),乔治亚州肿瘤研究中心,奥古斯塔大学

7/2015-现在                终身正教授(Tenured Professor, 乔治亚州研究联合杰出疫苗研究者(GRA Distinguished Vaccine Investigator),乔治亚州肿瘤研究中心,奥古斯塔大学

          

学术服务

A: 是以下学术杂志的审稿人(括号内是杂志影响因子):

1.      Archivum Immunologiae et Therapiae Experimentalis (2.818)

2.      BBA (Biochimica et Biophysica Acta) (4.554)

3.      BMC Medicine (7.28)

4.      BMC Cancer (3.319)

5.      Cancer Immunology, Immunotherapy (3.943)

6.      Cancer Letters (5.016)

7.      Cancer Research (9.284)

8.      Cell & Bioscience (3.21)

9.      Cell Death & Differentiation (8.385)

10.  Clinical and Experimental Pharmacology and Physiology (2.405)

11.  Current Cancer Therapy

12.  Cytotherapy (3.1)

13.  Digestive Diseases and Sciences (2.61)

14.  Future Virology (1.01)

15.  Gene and Immunity (3.789)

16.  Hepatology (11.711)

17.  Human Gene Therapy (3.623)

18.  International Journal of Cancer (5.007)

19.  Journal of Gene Medicine (1.953)

20.  Journal of Hematology and Oncology (4.93)

21.  Journal of Immunology (5.362)

22.  Journal for ImmunoTherapy of Cancer

23.  Journal of Internal Medicine (7.803)

24.  Journal of Investigative Dermatology (6.372)

25.  Melanoma Research (2.10)

26.  Molecular Immunology (3.0)

27.  Oncogene (8.559)

28.  Oncotarget (6.63)

29.  Oncoimmunology (6.283)

30.  PLSONE (3.73)

31.  PLSONE Pathogens (8.057)

32.  Scientific Reports (Nature) (5.228)

33.  Translational Research (5.03)

34.  Tumor Biology (2.84)

35.  Vaccines (3.485)

B. 参与以下单位(包括NIH)的基金审稿,

1.      Grant reviewer for the Chinese University of Hong Kong (Since 2006)   

2.      Member of GRU Intramural Grants Program Review Committee (Since 2008)

3.      NIH CII study section (ad hoc member, June of 2009)

4.      Biomedical Research Program and the Bankhead-Coley Cancer Research Program) (ad hoc grant reviewer, 2010)

5.      Grant reviewer for Florida Department of Health: James & Esther King (2010)

6.      Reviewer for VA Oncology Subcommittee Merit Award grant applications (2010)

7.      Reviewer for the Volkswagen Foundation (administered by the Ministry of Science and Culture (MWK) of the German State of Lower Saxony of Germany) for Research Projects (2010).

8.      Reviewer for the Volkswagen Foundation (administered by the Ministry of Science and Culture (MWK) of the German State of Lower Saxony of Germany) for Research Projects (2011).

9.      Reviewer for providing critiques to grant proposal from University of Wisconsin Department of Surgery (2011).

10.  Reviewer for AAAS Research Competitiveness Program (2014)

11.  NIH CII study section (ad hoc member, Feb 25-26, 2016)

C. 参加以下大学的职称评定

1.      External referee for the Promotion and Tenure committee of the Department of Pathology, University of Texas Medical Branch, Galveston, TX (2009).

2.      External referee for the Promotion and Tenure committee of the Department of Pathology, Microbiology, and Immunology, University of South Carolina, Columbia, SC, to evaluate the credential of applicants (2012).

3.      External referee for the Promotion and Tenure committee of the Department of Medicine, School of Medicine, St Louis University, St. Louis, MO, to evaluate the credential of applicant (2012).

4.      External Reviewer for UC Davis Faculty appointment (2015)

5.      External Reviewer for faculty promotion evaluation, University of South Carolina, School of Medicine (2015),

6.      External Reviewer for faculty promotion evaluation, St Louis University, School of Medicine (2016)

D. 以下学术委员会委员

1.      奥古斯塔大学校内基金评议(Member of Augusta University Institution Grant Review Committee since 2008, responsible for reviewing the following intramural grant applications:

a.       Pilot Study Research Program (PSRP),

b.       Interdisciplinary Research Program (IRP),

c.       Scientist Training Program (STP)

2.      研究生院分子医学专业委员(Member of Molecular Medicine Graduate Education Committee (MMGEC), GRU since 2009, responsible for designing curriculum, recruiting students, and organizing faculty research introduction to new students.  

E. 被邀请主持美国免疫学年会分会的主持人(Chair, Block Symposium, Section of Immunotherapy Vaccines, AAI Annual Meeting, May 2-6, 2014, Pittsburgh, PA

获得的研究基金


A.      正在进行的基金.

1.      R01 CA168912           PI: Dr. Yukai He    03/01/14 – 2/28/19   Direct cost: $269,250

NIH/NCI: Engineering alpha fetoprotein and glypican-3 to develop hepatoma (HCC) vaccines”

My Role: PI

Effort: 25%

The purpose of this project is to focus on study the potential of antigen engineering approaches including creation of DC-targeted tripartite virus-like-particles to generate effective HCC vaccines to prevent autochthonous HCC in mice.

Overlap: None

2.      Augusta University-Medical University of South Carolina collaborative grant: 2/1/2016 to 1/31/2017; Direct cost: $25,000. “Novel Immunotherapy of Myeloid Leukemia with CS3-CAR-T Cells,”

My Role: Co-PI

The goal of this is to create innovative CAR gene and CAR-T cells for myeloid leukemia immunotherapy.  

Overlap: None

B.      已经完成的基金

1.      R01 CA116444     PI: Yukai He       04/2007 - 01/2012; direct cost: $200,000/yr

NIH/NCI: “Mechanism of Eliciting Antitumor Cell Immunity Via Lentivector Immunization

Role: PI

This project propose to investigate the basic mechanism of inducing T cell immunity using lentivector mediated genetic immunization, which can be utilized for rational design of genetic vaccines for tumor and chronic infections.

2.      5K01AR047576   PI:  Yukai He    04/2002 – 3/2007; direct cost: $125,000/yr

NIH/NIAMS: “Regulation of Antitumor Immunity by DC Subsets

Role: PI

Effort: 100%

This project dissected the role of DC subsets in the elicitation of antitumor immunity. This was a career development award with the intention of becoming an independent investigator through the span of this grant. This K award provided a tremendous help for allowing me to integrate my gene therapy background with the purpose of developing genetic vaccines. I became a tenure track Assistant Professor in 2003 working in the field of genetic immunization using recombinant viral vectors.

3.      ACS        PI:  Dr. Yukai He             1998-1999; direct cost: $10,000

Combination gene therapy of HPV positive cancer with antisense RNA and Flt3 ligand genes

Role: PI

This study explored the increase of dendritic cells in mouse by using flt3 ligand gene delivery and the enhancement of antisense based gene therapy of HPV positive cancers.

4.      NSF of China       PI: Yukai He             1990-1992

Reversal of the HPV positive cervical carcinoma phenotype by delivering antisense and ribozyme expression vector DNA

5.       JDRF                     PI: Dr. Andrew Mellor             08/2008 - 07/2011

Creating local suppressive inflammation to block T1D progression

Role: co-I.

Effort: 5%

This study is to explore the potential of using IDO gene delivery for suppressing type 1 diabetes

       Overlap: No overlap with current proposal

6.      U01 AI083005      PI: Dr. Andrew Mellor      04/01/09-03/31/13

NIH/NIAID:  “Manipulating natural host immunoregulation via IDO during viral infection 

Role: co-I

Effort: 5%

This is a multi-institution consortium to study the role of IDO as a counter-regulatory mechanism during acute viral infection and anti-viral vaccination.

Overlap:  There is no scientific or budgetary overlap with the studies proposed. 

7.      Mason Trust Foundation    PI: Dr. Andrew Mellor      09/01/08-07/31/11

 “Innovative approaches to prolong transplant survival”  

Role: co-I

Effort: 3%

The goals of this project are to develop novel techniques for tolerance induction in solid-organ transplantation, including gene-transfer of recombinant IDO.   

Overlap:  There is no overlap with the studies proposed.

8.      R01 AI075165      PI: Dr. Andrew Mellor      5/22/2009– 4/30/2011

NIH/NIAID:               “T cell regulation by IDO-competent plasmacytoid dendritic cells”

            Role: Co-I

            Effort: 5%

            Major Goals: The goals of this project are to elucidate the etiology and T cell regulatory functions of a specialized subset of mouse plasmacytoid DCs that express the immunoregulatory enzyme indoleamine 2,3 dioxygenase (IDO)

            Overlap: None

专利:

1.       2010年获得一项美国专利(US Patent 7,662,793)。 2016年该专利和INDNantworks公司Founded by Dr. Patrick Soon-Shiong买去US Patent 7,662,793, Inventors: Yukai He, Jennifer R Grandis, and Leaf Huang. Title: “Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter”. This patent and IND have been licensed by Nantworks in Oct of 2016

2.       The hAFP特异的TCR专利正在申请之中。


获奖和荣誉(AWARDS/HONORS

3.

[打印]    [返回列表]